BCAL Diagnostics Limited (ASX:BDX)
Australia · Delayed Price · Currency is AUD 0.0860
+0.0160 (22.86%)
Sep 17, 2026, 3:34 PM AEST
BCAL Diagnostics Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Operating Revenue | 0.18 | 0.02 | - | - | 0.72 |
Other Revenue | 2.17 | 2.63 | 3.05 | 2.79 | - |
| 2.35 | 2.65 | 3.05 | 2.79 | 0.72 | |
Revenue Growth | -11.25% | -13.01% | 9.18% | 288.29% | 161.09% |
Gross Profit | 2.35 | 2.65 | 3.05 | 2.79 | 0.72 |
Selling, General & Admin | 3.71 | 3.62 | 3.61 | 2.76 | 1.46 |
Research & Development | 4.67 | 4.46 | 4.36 | 4.47 | 1.91 |
Operating Expenses | 9.42 | 9.77 | 9.13 | 7.58 | 3.77 |
Operating Income | -7.07 | -7.12 | -6.08 | -4.79 | -3.05 |
Interest Expense | -0.35 | -0.09 | -0.1 | -0.02 | - |
Interest & Investment Income | 0.03 | 0.18 | 0.05 | 0.06 | - |
Other Non Operating Income (Expenses) | -0.15 | -0.21 | -0.27 | -0.32 | -0.34 |
EBT Excluding Unusual Items | -7.53 | -7.24 | -6.4 | -5.06 | -3.39 |
Gain (Loss) on Sale of Investments | 0.16 | - | - | - | - |
Pretax Income | -7.37 | -7.24 | -6.4 | -5.06 | -3.39 |
Net Income | -7.37 | -7.24 | -6.4 | -5.06 | -3.39 |
Net Income to Common | -7.37 | -7.24 | -6.4 | -5.06 | -3.39 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 368 | 360 | 246 | 211 | 204 |
Shares Outstanding (Diluted) | 368 | 360 | 246 | 211 | 204 |
Shares Change | 2.22% | 46.04% | 16.75% | 3.24% | 51.65% |
EPS (Basic) | -0.02 | -0.02 | -0.03 | -0.02 | -0.02 |
EPS (Diluted) | -0.02 | -0.02 | -0.03 | -0.02 | -0.02 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | -6.62 | -6.92 | -5.67 | -6.41 | -3.25 |
Free Cash Flow Per Share | -0.02 | -0.02 | -0.02 | -0.03 | -0.02 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -300.54% | -268.73% | -199.51% | -171.55% | -424.13% |
Profit Margin | -313.38% | -273.21% | -210.07% | -181.39% | -471.08% |
Free Cash Flow Margin | -281.40% | -261.23% | -186.23% | -229.72% | -451.54% |
EBITDA | -6.59 | -6.39 | -5.73 | -4.73 | -3.03 |
EBITDA Margin | -280.16% | -241.18% | -188.16% | -169.45% | - |
D&A For EBITDA | 0.48 | 0.73 | 0.35 | 0.06 | 0.02 |
EBIT | -7.07 | -7.12 | -6.08 | -4.79 | -3.05 |
EBIT Margin | - | -268.73% | -199.51% | -171.55% | - |